Therefore, the future of EGFR inhibition in CC may lie not with monoclonal antibodies in the salvage setting, but with next-generation EGFR-TKIs strategically combined with established radical modalities such as chemoradiation. This evidence concerns the gene EGFR and cholangiocarcinoma.